老年创伤患者凝血酶激活纤溶抑制物水平与脓毒症风险的相关性分析

丁汝梅, 赵国强, 胥丰, 等. 老年创伤患者凝血酶激活纤溶抑制物水平与脓毒症风险的相关性分析[J]. 临床急诊杂志, 2021, 22(5): 329-334. doi: 10.13201/j.issn.1009-5918.2021.05.008
引用本文: 丁汝梅, 赵国强, 胥丰, 等. 老年创伤患者凝血酶激活纤溶抑制物水平与脓毒症风险的相关性分析[J]. 临床急诊杂志, 2021, 22(5): 329-334. doi: 10.13201/j.issn.1009-5918.2021.05.008
DING Rumei, ZHAO Guoqiang, XU Feng, et al. Correlation between the level of thrombin-activated fibrinolysis inhibitor and the risk of sepsis in elderly trauma patients[J]. J Clin Emerg, 2021, 22(5): 329-334. doi: 10.13201/j.issn.1009-5918.2021.05.008
Citation: DING Rumei, ZHAO Guoqiang, XU Feng, et al. Correlation between the level of thrombin-activated fibrinolysis inhibitor and the risk of sepsis in elderly trauma patients[J]. J Clin Emerg, 2021, 22(5): 329-334. doi: 10.13201/j.issn.1009-5918.2021.05.008

老年创伤患者凝血酶激活纤溶抑制物水平与脓毒症风险的相关性分析

  • 基金项目:

    贵州省贵阳市科技计划项目(No:[2019]9-5-17)

详细信息
    通讯作者: 董志军,E-mail:psbydrmly@163.com
  • 中图分类号: R631

Correlation between the level of thrombin-activated fibrinolysis inhibitor and the risk of sepsis in elderly trauma patients

More Information
  • 目的:分析中老年创伤患者凝血酶激活纤溶抑制物水平与脓毒症风险的相关性分析。方法:入选2018年7月—2020年7月期间于我院急诊外科进行诊治的中老年创伤患者460例进行分析,根据患者在住院期间是否发生脓毒症分为对照组及脓毒症组。比较两组的一般资料、实验室指标[包括凝血酶激活的纤溶抑制物(TAFI)、D-二聚体(DD)等]等项目;应用多因素Logistic回归分析影响创伤患者发生脓毒症的相关因素,应用ROC曲线分析各因素预测创伤患者发生脓毒症的风险。结果:纳入研究的460例创伤患者,有14例脱落,有效分析446例,其中55例患者在治疗过程中出现脓毒症被列为脓毒症组,391例患者为对照组,脓毒症发生率为12.33%。两组的性别、病程、WBC和PLT等临床资料比较,差异无统计学意义(P>0.05);但脓毒症组年龄、PCT、CRP及DD均高于对照组(P<0.05);且脓毒症组ATⅢ及TAFI均低于对照组(P<0.05);多因素Logistic回归分析显示:PCT、CRP和DD是影响创伤患者发生脓毒症的独立危险因素,而TAFI是影响创伤患者发生脓毒症的保护性因素。ROC曲线显示:TAFI预测创伤患者发生脓毒症的诊断效能明显高于PCT、CRP和DD的预测价值,其最佳截点:≤22.92μg/mL,此时诊断的敏感度为78.23%、特异度为85.92%。结论:中老年创伤患者早期TAFI与发生脓毒症风险呈负相关关系,早期监测有助于临床及时调整治疗方案,预防脓毒症的发生及改善创伤患者的预后。
  • 加载中
  • [1]

    GBD 2016 Occupational Chronic Respiratory Risk Factors Collaborators,GBD 2016 occupational chronic respiratory risk factors collaborators.Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures:a systematic analysis for the Global Burden of Disease Study 2016[J].Occup Environ Med,2020,77(3):142-150.

    [2]

    Hanke A A,Horstmann H,Wilhelmi M.Point-of-care monitoring for the management of trauma-induced bleeding[J].Curr Opin Anaesthesiol,2017,30(2):250-256.

    [3]

    徐明.2019年第5版《欧洲创伤后大出血与凝血功能障碍管理指南》解读[J].临床药物治疗杂志,2020,18(1):11-13.

    [4]

    Wu Y,Luo L,Niu T,et al.Evaluation of the new Chinese Disseminated Intravascular Coagulation Scoring System in critically ill patients:A multicenter prospective study[J].Sci Rep,2017,7(1):9057.

    [5]

    Iba T,Thachil J.Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis[J].J Intensive Care,2017,5:56.

    [6]

    Morishima Y,Kamisato C,Honda Y.Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis[J].J Thromb Thrombolysis,2020,49(1):94-99.

    [7]

    沈岩.创伤性凝血病的诊治[J].创伤外科杂志,2015,17(5):478-481.

    [8]

    王正国.创伤救治研究新进展[J].中华急诊医学杂志,2009,18(4):341-343.

    [9]

    中国医师协会急诊医师分会,中国研究型医院学会休克与脓毒症专业委员会.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J].临床急诊杂志,2018,19(9):567-588.

    [10]

    Fu HP,Zhang YX,Wei YF,et al.Correlation analysis between both the platelet-to-lymphocyte ratio and maximum amplitude of thrombus and death in severe traumatic patients[J].Med J Chin PLA,2018,43(6):S09-513.

    [11]

    Petros S.Trauma-induced coagulopathy[J].Hamostaseologie,2019,39(1):20-27.

    [12]

    Emergency Medicine Branch of Chinese Medical Doctor Association,People's Liberation Army Professional Committee of Emergency Medicine,People's Liberation Army Professional Committee of Critical Care Medicine,et al.Chinese emergency medicine expert consensus on diagnosis and treatment of traumatic hemorrhagic shock[J].Med J Chin PLA,2017,42(12):1029-1038.

    [13]

    Hayakawa M.Pathophysiology of trauma-induced coagulopathy:disseminated intravascular coagulation with the fibrinolytic phenotype[J].J Intensive Care,2017,5:14.

    [14]

    Griemert EV,Schwarzmaier SM,Hummel R,et al.Plasminogen activator inhibitor-1 augments damage by impairing fibrinolysis after traumatic brain injury[J].Ann Neurol,2019,85(5):667-680.

    [15]

    Patti G,Cerchiara E,Bressi E,et al.Endothelial Dysfunction,Fibrinolytic Activity,and Coagulation Activity in Patients With Atrial Fibrillation According to Type Ⅱ Diabetes Mellitus Status[J].Am J Cardiol,2020,125(5):751-758.

    [16]

    Naumann DN,Hazeldine J,Davies DJ,et al.Endotheliopathy of trauma is an on-scene phenomenon,and is associated with multiple organ dysfunction syndrome:A prospective observational study[J].Shock,2018,49(4):420-428.

    [17]

    Johansson PI,Stensballe J,Ostrowski SR.Erratum to:Shock induced endotheliopathy(SHINE)in acute critical illness-a unifying pathophysiologic mechanism[J].Crit Care,2017,21(1):187.

    [18]

    Spahn DR,Bouillon B,Cerny V,et al.The European guideline on management of major bleeding and coagulopathy following trauma:fifth edition[J].Crit Care,2019,23(1):98.

    [19]

    Yoshiyuki M,Yuko H.A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma:dependent on thrombin-activatable fibrinolysis inhibitor[J].J Thromb Thrombolysis,2019,48(1):103-110.

  • 加载中
计量
  • 文章访问数:  194
  • PDF下载数:  355
  • 施引文献:  0
出版历程
收稿日期:  2020-12-22

目录